The Prognosis Of Peroxiredoxin Family In Breast Cancer

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Dec 10

PMID 31814764

Citations 20

Authors

Gang Wang

Wan-Chao Zhong

Yi-Hui Bi

Si-Yue Tao

Hai Zhu

Hai-Xing Zhu

A-Man Xu

Affiliations

Soon will be listed here.

Abstract

Purpose: PRDX (Peroxiredoxin) family has involved in breast cancer tumorigenesis from the evidence obtained from cell lines, human tissues and mouse models. Nonetheless, the diversified expression patterns, coupled with the prognostic values of PRDX family, still require explanation. This study aimed at investigating the clinical importance and biological of PRDXs in breast cancer.

Patients And Methods: Specimens of paraffin sections used for immunohistochemistry were collected from the hospital and the remaining patient information was retrieved from online databases. The expression and survival data of PRDXs in patients with breast cancer were from ONCOMINE, GEPIA, Kaplan-Meier Plotter. cBioPortal, Metascape, String, Cytoscape and DAVID were used to predict functions and pathways of the changes in PRDXs and their frequently altered neighbor genes. Immunohistochemistry was used to detect the expression of PRDXs in breast cancer.

Results: We discovered the expression levels of PRDX1-5 were higher in breast cancer tissues than in normal tissues, whereas the expression level of PRDX6 was observed as lower in the former one in comparison with that of the latter one. There existed a correlation between the expression levels of PRDX4, 5 and the advanced tumor stage. Survival analysis revealed that the expression of PRDXs were all associated with relapse-free survival (RFS) in all of the patients with breast cancer. Eventually, we discovered significant regulation of the cellular oxidant detoxification and detoxification of ROS by the PRDX changes, together with obtaining the core modules of genes (TXN, TXN2, TXNRD1, TXNRD2, GPX1 and GPX2) linked to the PRDX family of genes in breast cancer.

Conclusion: The PRDX family is widely involved in the development of breast cancer and affects the prognosis of patients. The functions and pathways of the changes in PRDXs and their frequently altered neighbor genes can be further verified by wet experiments.

Citing Articles

In Silico Analysis of Non-Conventional Oxidative Stress-Related Enzymes and Their Potential Relationship with Carcinogenesis.

Seiva F, Agneis M, de Almeida M, Caputo W, de Souza M, das Neves K Antioxidants (Basel). 2024; 13(11).

PMID: 39594421 PMC: 11591236. DOI: 10.3390/antiox13111279.

Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.

Sutherland L, Lang J, Gonzalez-Juarbe N, Pickett B Curr Issues Mol Biol. 2024; 46(7):7114-7133.

PMID: 39057065 PMC: 11275280. DOI: 10.3390/cimb46070424.

Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma.

Lei P, Yu L, Sun X, Hao J, Shi W, Sun H Med Oncol. 2024; 41(2):48.

PMID: 38177789 DOI: 10.1007/s12032-023-02265-6.

Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite.

Ali R, Alhaj Sulaiman A, Memon B, Pradhan S, Algethami M, Aouida M Cells. 2023; 12(23).

PMID: 38067110 PMC: 10705171. DOI: 10.3390/cells12232682.

Single-Cell Transcriptional and Epigenetic Profiles of Male Breast Cancer Nominate Salient Cancer-Specific Enhancers.

Kim H, Wisniewska K, Regner M, Thennavan A, Spanheimer P, Franco H Int J Mol Sci. 2023; 24(17).

PMID: 37685859 PMC: 10487538. DOI: 10.3390/ijms241713053.

References

Liu X, Feng R, Du L . The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett. 2010; 584(14):3185-92. DOI: 10.1016/j.febslet.2010.06.002. View

Chae H, Oubrahim H, Park J, Rhee S, Chock P . Protein glutathionylation in the regulation of peroxiredoxins: a family of thiol-specific peroxidases that function as antioxidants, molecular chaperones, and signal modulators. Antioxid Redox Signal. 2011; 16(6):506-23. PMC: 3270059. DOI: 10.1089/ars.2011.4260. View

Wang X, Wang H, Li X . Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumour Biol. 2013; 34(4):2275-81. DOI: 10.1007/s13277-013-0769-0. View

Jo M, Yun H, Park K, Park M, Kim T, Pak J . Lung tumor growth-promoting function of peroxiredoxin 6. Free Radic Biol Med. 2013; 61:453-63. DOI: 10.1016/j.freeradbiomed.2013.04.032. View

Jiang L, Ren J, Xiao X, Tang Y, Weng H, Yang Q . Proteomic analysis of bladder cancer by iTRAQ after Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene treatment. Biol Chem. 2013; 394(10):1333-42. DOI: 10.1515/hsz-2013-0201. View

Castellana B, Escuin D, Perez-Olabarria M, Vazquez T, Munoz J, Peiro G . Genetic up-regulation and overexpression of PLEKHA7 differentiates invasive lobular carcinomas from invasive ductal carcinomas. Hum Pathol. 2012; 43(11):1902-9. DOI: 10.1016/j.humpath.2012.01.017. View

Turner-Ivey B, Manevich Y, Schulte J, Kistner-Griffin E, Jezierska-Drutel A, Liu Y . Role for Prdx1 as a specific sensor in redox-regulated senescence in breast cancer. Oncogene. 2013; 32(45):5302-14. PMC: 3936261. DOI: 10.1038/onc.2012.624. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Soini Y, Kinnula V . High association of peroxiredoxins with lung cancer. Lung Cancer. 2012; 78(2):167. DOI: 10.1016/j.lungcan.2012.08.013. View

10.

Byun J, Kim S, Kim K, Kang M, Jeong D, Lee D . Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer. Oncol Lett. 2018; 15(4):5111-5118. PMC: 5835875. DOI: 10.3892/ol.2018.7909. View

11.

Deighton R, Le Bihan T, Martin S, Gerth A, McCulloch M, Edgar J . Interactions among mitochondrial proteins altered in glioblastoma. J Neurooncol. 2014; 118(2):247-256. PMC: 4048470. DOI: 10.1007/s11060-014-1430-5. View

12.

Zhao H, Langerod A, Ji Y, Nowels K, Nesland J, Tibshirani R . Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 2004; 15(6):2523-36. PMC: 420079. DOI: 10.1091/mbc.e03-11-0786. View

13.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

14.

Goncalves K, Sullivan K, Phelan S . Differential expression and function of peroxiredoxin 1 and peroxiredoxin 6 in cancerous MCF-7 and noncancerous MCF-10A breast epithelial cells. Cancer Invest. 2012; 30(1):38-47. DOI: 10.3109/07357907.2011.629382. View

15.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

16.

Bajor M, Zych A, Graczyk-Jarzynka A, Muchowicz A, Firczuk M, Trzeciak L . Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. Br J Cancer. 2018; 119(7):873-884. PMC: 6189216. DOI: 10.1038/s41416-018-0263-y. View

17.

Stresing V, Baltziskueta E, Rubio N, Blanco J, Arriba M, Valls J . Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene. 2012; 32(6):724-35. DOI: 10.1038/onc.2012.93. View

18.

Wang X, He S, Sun J, Delcuve G, Davie J . Selective association of peroxiredoxin 1 with genomic DNA and COX-2 upstream promoter elements in estrogen receptor negative breast cancer cells. Mol Biol Cell. 2010; 21(17):2987-95. PMC: 2929992. DOI: 10.1091/mbc.E10-02-0160. View

19.

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H . Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14(5):518-27. DOI: 10.1038/nm1764. View

20.

Tiedemann K, Sadvakassova G, Mikolajewicz N, Juhas M, Sabirova Z, Tabaries S . Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. Transl Oncol. 2018; 12(3):462-474. PMC: 6305809. DOI: 10.1016/j.tranon.2018.11.014. View